[1] Siegel RL, Miller KD, Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
[2] 徐梦娇,童晓文.游离DNA异常甲基化在卵巢癌中的研究进展[J].外科研究与新技术,2016,5(2):132-135.
[3] Bookman MA.Optimal primary therapy of ovarian cancer: Table 1[J].Ann Oncol,2016,27 (suppl 1):i58-i62.
[4] Wright AA, Bohlke K, Armstrong DK, et al.Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2016,34 (28):3460-3473.
[5] Marcus CS, Maxwell GL, Darcy KM, et al.Current approaches and challenges in managing and monitoring treatment response in ovarian cancer[J].J Cancer,2014,5(1):25-30.
[6] Fire A, Xu S, Montgomery MK, et al.Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J].Nature,1998,391(6669):806-811.
[7] Smalheiser NR.The search for endogenous siRNAs in the mammalian brain[J].Exp Neurol,2012,235(2):455-463.
[8] Ipsaro JJ, Joshua-Tor L.From guide to target:molecular insights into eukaryotic RNA-interference machinery[J].Nat Struct Mol Biol,2015,22(1):20-28.
[9] Tsai HY, Chen CC, Conte D, et al.A ribonuclease coordinates siRNA amplification and mRNA cleavage during RNAi[J].Cell,2015,160(3):407-419.
[10] Wittrup A, Lieberman J.Knocking down disease: a progress report on siRNA therapeutics[J].Nat Rev Genet,2015,16(9):543-552.
[11] Wang J, Lu Z, Wientjes MG, et al.Delivery of siRNA therapeutics: barriers and carriers[J].The AAPS Journal,2010,12(4):492-503.
[12] Yan F, Shao LJ, Hu XY.Knockdown of UHRF1 by lentivirus-mediated shRNA inhibits ovarian cancer cell growth[J].Asian Pac J Cancer Prev,2015,16(4):1343-1348.
[13] Zhu YF, Gao GL, Tang SB, et al.Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro[J].Asian Pac J Trop Med,2013,6(4):265-272.
[14] Chen X, Zhang Y, Tang C, et al.Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis[J].Int J Pharm,2017,529(1-2):102-115.
[15] Liu L, Zheng M, Librizzi D, et al.Efficient and tumor targeted siRNA delivery by polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol)[J].Mol Pharm,2016,13(1):134-143.
[16] Shen J, Kim HC, Su H, et al.Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics[J].Theranostics,2014,4(5):487-497.
[17] Nascimento AV, Gattacceca F, Singh A, et al.Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models[J].Nanomedicine (Lond),2016,11(7):767-781.
[18] Teo PY, Yang C, Whilding LM, et al.Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine:strategies to enhance T cell killing[J].Adv Healthc Mater,2015,4(8):1180-1189.
[19] Guo S, Huang Y, Jiang Q, et al.Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte[J].ACS Nano,2010,4(9):5505-5511.
[20] Meng H, Mai WX, Zhang H, et al.Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo[J].ACS Nano,2013,7(2):994-1005.
[21] Chen Y, Xu M, Guo Y, et al.Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle[J].Nanotechnology,2017,28(2):25-101.
[22] Januchowski R, Sterzynska K, Zaorska K, et al.Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines[J].J Ovarian Res,2016,9(1):65.
[23] Kelly RJ, Thomas A, Rajan A, et al.A phase I/II study of sepantronium bromide (YM155,survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer[J].Ann Oncol,2013,24(10):2601-2606.
[24] Turner JG, Dawson JL, Grant S, et al.Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors[J].J Hematol Oncol,2016,9(1):73.
[25] Kovalev AA, Tsvetaeva DA, Grudinskaja TV.Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the develop-ment of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer[J].Exp Oncol,2013,35(4):287-290.
[26] Zhang Y, Sriraman SK, Kenny HA, et al.Reversal of chemoresistance in oivarian cancer by co-delivery of a p-glycoprotein inhibitor and paclitaxel in a liposomal platform[J].Mol Cancer Ther,2016,15(10):2282-2293.
[27] Zheng X, Andruska N, Lambrecht MJ, et al.Targeting multidrug-resistant ovarian cancer through estrogen receptor alpha dependent ATP depletion caused by hyperactivation of the unfolded protein response[J].Oncotarget,2018,9(19):14741-14753.
[28] Deng J, Guo Y, Jiang Z, et al.Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella[J].J Obstet Gynaecol Res,2015,41(4):615-622.
[29] Guo N, Gao C, Liu J, et al.Reversal of ovarian cancer multidrug resistance by a combination of LAH4-L1-siMDR1 nanocomplexes with chemotherapeutics[J].Mol Pharm,2018,15(5):1853-1861.
[30] Risnayanti C, Jang YS, Lee J, et al.PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer[J].Sci Rep,2018,8(1):7498.
[31] Li L, Mao X, Qin X, et al.Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2[J].Oncol Lett,2016,12(1):93-96.
[32] Liu X, Dong J, Cai W, et al.The effect of thymoquinone on apoptosis of SK-OV-3 ovarian cancer cell by regulation of Bcl-2 and Bax[J].Int J Gynecol Cancer,2017,27(8):1596-1601.
[33] He C, Lu K, Liu D, et al.Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells[J].J Am Chem Soc,2014,136(14):5181-5184.
[34] Kucukgoz Gulec U, Gumurdulu D, Guzel AB, et al.Prognostic importance of survivin,Ki-67,and topoisomerase II alpha in ovarian carcinoma[J].Arch Gynecol Obstet,2014,289(2):393-398.
[35] Yang X, Iyer AK, Singh A, et al.Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer[J].Pharm Res,2015,32(6):2097-2109.
[36] Salzano G, Navarro G, Trivedi MS, et al.Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J].Mol Cancer Ther,2015,14(4):1075-1084.
